{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:54Z","timestamp":1789753434170,"version":"4.0.1"},"reference-count":29,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2016,3,3]]},"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To examine <jats:italic>TOP2A<\/jats:italic> copy number, TOP2A expression, and its prognostic value in uterine leiomyosarcoma (LMS) and other benign smooth muscle tumours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed 37 patients treated for uterine LMS with immunohistochemistry for protein expression and fluorescence in situ hybridisation (FISH) for copy number. Twelve cases of leiomyoma variants (LMVs), 4 smooth muscle tumours of uncertain malignant potential (STUMP) and 23 leiomyomas (LMs) were also included.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighteen patients with LMS (48.6%) were International Federation of Gynecology and Obstetrics (FIGO) stage I, six (16.2%) were stage II, four (10.8%) were stage III, and nine (24.3%) were stage IV. Twenty-one (56.8%) patients with LMS showed high expression of TOP2A. Greater TOP2A levels were found in patients with stage \u2265II disease compared with stage I and also in high mitotic index tumours (&gt;20\/10 HPF (high power field)). Eleven (36.7%) cases had abnormal <jats:italic>TOP2A<\/jats:italic> copy numbers. There was no link between <jats:italic>TOP2A<\/jats:italic> copy number and TOP2A expression. All patients with benign smooth muscle tumours had low TOP2A immunohistochemical expression and one (7.7%) patient had <jats:italic>TOP2A<\/jats:italic> amplification. TOP2A expression and <jats:italic>TOP2A<\/jats:italic> copy number had no impact on disease outcomes. Only the presence of disease outside of the uterus negatively impacted survival compared with early disease (53.4 vs 15.8\u2005months; p&lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TOP2A is highly expressed in advanced LMS but not in non-malignant diseases. TOP2A expression does not correlate with FISH results and does not predict outcome. TOP2A levels are higher in high-mitotic index tumours and in more advanced stages of disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2015-203561","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T00:00:39Z","timestamp":1458345639000},"page":"884-889","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["<i>TOP2A<\/i> copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma"],"prefix":"10.1136","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-5582","authenticated-orcid":false,"given":"Glauco","family":"Baiocchi","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Lu\u00eds Visoni","family":"Poliseli","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"De Brot","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Mantoan","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Nunes","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Chaves","family":"Faloppa","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vassallo","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Augusto","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Werneck","family":"Cunha","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, AC Camargo Cancer Center, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"2025092509185325000_69.10.884.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.023"},{"key":"2025092509185325000_69.10.884.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.2820710440"},{"key":"2025092509185325000_69.10.884.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.027"},{"key":"2025092509185325000_69.10.884.4","unstructured":"Kurman RJ , Carcangiu ML , Herrington CS , et al . World Health Organization classification of tumors of female reproductive organs. 4th edn. Lyon: IARC Press, 2014."},{"key":"2025092509185325000_69.10.884.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00137-9"},{"key":"2025092509185325000_69.10.884.6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181574d1e"},{"key":"2025092509185325000_69.10.884.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.09.026"},{"key":"2025092509185325000_69.10.884.8","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0b013e31815ea7f5"},{"key":"2025092509185325000_69.10.884.9","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.27113"},{"key":"2025092509185325000_69.10.884.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2007.02699.x"},{"key":"2025092509185325000_69.10.884.11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/oxfordjournals.annonc.a058584","article-title":"DNA topoisomerase I and II as targets for rational design of new anticancer drugs","volume":"4","author":"Cummings","year":"1993","journal-title":"Ann Oncol"},{"key":"2025092509185325000_69.10.884.12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803513105"},{"key":"2025092509185325000_69.10.884.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4716"},{"key":"2025092509185325000_69.10.884.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6449"},{"key":"2025092509185325000_69.10.884.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64952-8"},{"key":"2025092509185325000_69.10.884.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.05.008"},{"key":"2025092509185325000_69.10.884.17","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.038281"},{"key":"2025092509185325000_69.10.884.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.01.068"},{"key":"2025092509185325000_69.10.884.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.10.001"},{"key":"2025092509185325000_69.10.884.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2962"},{"key":"2025092509185325000_69.10.884.21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2184-3"},{"key":"2025092509185325000_69.10.884.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2009.03231.x"},{"key":"2025092509185325000_69.10.884.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.03.018"},{"key":"2025092509185325000_69.10.884.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.06.002"},{"key":"2025092509185325000_69.10.884.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2006.11.012"},{"key":"2025092509185325000_69.10.884.26","doi-asserted-by":"publisher","DOI":"10.3109\/02841869509127189"},{"key":"2025092509185325000_69.10.884.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23245"},{"key":"2025092509185325000_69.10.884.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3058"},{"key":"2025092509185325000_69.10.884.29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11586"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2015-203561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:18:57Z","timestamp":1758817137000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2015-203561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,20]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/jclinpath-2015-203561"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2015-203561","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}